Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04215978 · ClinicalTrials.gov registry record · Phase 1
Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors
A Phase 1 study of Non-Small Cell Lung Cancer and Advanced Solid Tumor, sponsored by BeiGene.
- Completed
- Registry status
- Phase 1
- Development phase
- 204
- Enrollment target
- 20
- Study locations
NCT04215978 is a Phase 1 study of Non-Small Cell Lung Cancer and Advanced Solid Tumor that has completed, run by BeiGene. The registered enrollment target is 204 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT04215978, a Phase 1 study of Non-Small Cell Lung Cancer and Advanced Solid Tumor, has completed, sponsored by BeiGene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 204 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the safety and tolerability of BGB-A445 alone and in combination with tislelizumab in participants with advanced solid tumors; and to determine the maximum tolerated dose(s) (MTD) or maximum administered dose(s) (MAD) and recommended Phase 2 doses (RP2D) of BGB-A445 alone and in combination with tislelizumab.
Conditions Studied
Interventions
- DRUG BGB-A445
- DRUG tislelizumab
Study Locations (20)
Victoria
- Monash Health - Clayton
- Peter Maccallum Cancer Centre - Melbourne
- Nucleus Network - Melbourne
Other
- University of Malaya Medical Centre - Kuala Lumpur
- Sarawak General Hospital - Kuching
- Auckland City Hospital - Auckland
California
- Valkyrie Clinical Trials - Los Angeles
- California Cancer Associates for Research & Excellence (cCARE) - San Diego
Queensland
- Pindara Private Hospital - Benowa
- Princess Alexandra Hospital - Brisbane
Shandong
- Jinan Central Hospital - Jinan
- Linyi Cancer Hospital - Linyi
Zhejiang
- Sir Run Run Shaw Hospital Zhejiang University School of Medicine - Hangzhou
- Zhejiang Cancer Hospital - Hangzhou
Pennsylvania
- UPMC Hillman Cancer Center (Univ Of Pittsburgh) - Pittsburgh
New South Wales
- Blacktown Cancer And Haematology Centre - Blacktown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 204 participants |
| Start Date | 2020-01-30 |
| Est. Completion | 2025-01-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04215978
The ClinicalTrials.gov registry entry for NCT04215978 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 204 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (69% lower). The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which BGB-A445 is the first listed.
NCT04215978 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Victoria, Other, California.
Frequently Asked Questions
What is clinical trial NCT04215978 about?
NCT04215978 is a clinical study titled "Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors". The purpose of this study is to assess the safety and tolerability of BGB-A445 alone and in combination with tislelizumab in participants with advanced solid tumors; and to determine the maximum tolerated dose(s) (MTD) or maximum administered dose(s) (MAD) and recommended Phase 2 doses (RP2D) of BGB...
What is the current status of trial NCT04215978?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 204 participants. The study started on 2020-01-30. Estimated completion is 2025-01-24.
What conditions does trial NCT04215978 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma (HNSCC), Nasopharyngeal Carcinoma (NPC).
What interventions are being tested in trial NCT04215978?
The interventions under investigation include: BGB-A445 (DRUG), tislelizumab (DRUG).
Who is sponsoring clinical trial NCT04215978?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04215978 being conducted?
This trial has 20 study locations across California, Pennsylvania, New South Wales, Queensland, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.